Sierra oncology, inc. (SRRA)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Sep'14Jun'14
Operating expenses:
Research and development

54,703

53,249

43,024

45,824

42,881

41,078

37,582

32,074

30,483

30,157

28,428

33,346

35,267

33,895

36,101

32,073

27,696

26,356

20,766

25,188

0

0

0

General and administrative

14,922

13,743

13,598

13,585

14,284

14,339

13,991

13,631

12,736

12,462

12,619

12,801

13,349

14,180

14,187

13,965

12,008

9,472

7,096

5,149

0

0

0

Total operating expenses

69,625

66,992

56,622

59,409

57,165

55,417

51,573

45,705

43,219

42,619

41,047

46,147

48,616

48,075

50,288

46,038

39,704

35,828

27,862

30,337

0

0

0

Loss from operations

-69,625

-66,992

-56,622

-59,409

-57,165

-55,417

-51,573

-45,705

-43,219

-42,619

-41,047

-46,147

-48,616

-48,075

-50,288

-46,038

-39,704

-35,828

-27,862

-30,337

0

0

0

Other income (expense), net:
Changes in fair value of warrant liabilities

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

17,443

17,946

10,806

0

0

0

Other income, net

-301

-517

1,408

1,599

1,833

1,780

1,587

1,333

936

760

598

461

364

351

277

218

124

66

70

72

0

0

0

Total other income (expense), net

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-17,377

-17,876

-10,734

0

0

0

Loss before provision for (benefit from) income taxes, net

-107,092

-88,435

-55,214

-57,810

-55,332

-53,637

-49,986

-44,372

-42,283

-41,859

-40,449

-45,686

-48,252

-47,724

-50,011

-53,307

-55,697

-53,205

-45,738

-41,071

0

0

0

Provision for (benefit from) income taxes, net

63

-160

-118

-50

-490

-302

-335

-293

165

156

215

192

169

143

66

66

53

55

0

0

0

-

-

Net loss and comprehensive loss

-107,155

-88,275

-55,096

-57,760

-54,842

-53,335

-49,651

-44,079

-42,448

-42,015

-40,664

-45,878

-48,421

-47,867

-50,077

-53,373

-55,750

-53,260

-45,763

-41,082

0

0

0

Adjustment to redemption value on redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

374,015

379,606

194,309

0

0

0

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-453,184

-451,278

-235,391

0

0

0

Net loss per common share, basic and diluted

-3.14

-22.93

-0.17

-0.20

-7.00

-29.60

-0.21

-0.16

-0.19

-33.03

-0.19

-0.20

-0.26

-0.30

-0.50

-0.43

-0.35

96.49

-11.03

-104.10

-12.83

-9.37

-55.04

Weighted-average shares used in computing net loss per common share, basic and diluted

10,156

-139,584

74,688

74,688

1,862

-201,316

74,347

74,320

59,722

-142,143

52,268

52,268

42,596

30,368

30,331

30,191

30,070

30,445

24,167

1,499

1,485

1,019

920